# Gypsy Basin Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gypsy-basin-genomics

- Industry: Healthcare
- Headquarters: New York, US
- Website: www.gypsybaygenomics.com/
- Latest round: Seed (Feb 16, 2021)
- Investors on record: 2

## About

Gypsy Basin Genomics specializes in advanced genomic sequencing and analysis, enhancing healthcare outcomes through personalized medicine and innovative diagnostic tools.Founded in 2018 in New York, US, Gypsy Basin Genomics, Inc. focuses on genomic solutions aimed at improving healthcare. The company was established by Joseph Sullivan. In February 2021, it raised seed funding from SOSV and IndieBio, marking its investment target.Gypsy Basin Genomics specializes in advanced genomic sequencing and analysis solutions designed to enhance healthcare outcomes and personalized medicine. Their core offerings include a suite of genomic diagnostic tools that enable clinicians and researchers to identify genetic predispositions to various diseases and tailor treatment plans accordingly. The services focus on areas such as oncology, rare genetic disorders, and precision medicine, facilitating early detection and effective intervention strategies. Their clientele includes hospitals, research institutions, and biotech companies across North America and Europe, where the demand for personalized healthcare solutions is rapidly growing. The products are designed to integrate seamlessly into existing healthcare infrastructure, ensuring accessibility for end users, including healthcare providers and patients.Gypsy Basin Genomics operates on a business-to-business (B2B) model, providing subscription-based services and partnerships with healthcare providers and research institutions. Revenue is generated primarily through the sale of their genomic diagnostic tools and subscription plans that offer data analysis and ongoing support. Healthcare institutions may enter into annual contracts that include a set number of sequencing tests and analysis reports, tailored to their specific needs. The pricing structure reflects the complexity and volume of services provided, with flagship products commanding premium pricing. These transactions are structured to ensure long-term partnerships, fostering collaborative relationships that enhance the value of genomic insights delivered to clinicians and researchers.Gypsy Basin Genomics aims to expand its product line with new genomic diagnostic tools expected to launch in late 2023, targeting enhanced analytics for oncology and rare disorders. The company plans to enter the European market by 2024 to meet growing demand for personalized healthcare solutions. The seed funding raised in February 2021 will support product development and market entry strategies, ensuring the necessary resources are allocated for successful expansion.

## Funding rounds

- Seed, Feb 16, 2021 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed